Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Biodesix Inc

Healthcare US BDSX

16.1USD
0.66(4.27%)

Last update at 2026-06-03T20:13:00Z

Day Range

15.2816.10
LowHigh

52 Week Range

3.4420.21
LowHigh

Fundamentals

  • Previous Close 15.44
  • Market Cap129.88M
  • Volume20795
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-22.09600M
  • Revenue TTM88.50M
  • Revenue Per Share TTM11.72
  • Gross Profit TTM 71.78M
  • Diluted EPS TTM-4.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -35.26500M -42.93100M -52.14600M -65.44700M -43.15900M
Minority interest - - - - -
Net income -35.26500M -42.93100M -52.14600M -80.38800M -44.48000M
Selling general administrative 87.55M 80.45M 67.76M 61.46M 50.52M
Selling and marketing expenses - - - 61.46M 50.52M
Gross profit 66.59M 55.75M 36.08M 24.06M 23.99M
Reconciled depreciation 5.60M 5.46M 5.85M 5.84M 3.18M
Ebit -27.54900M -34.67300M -42.61000M -50.50600M -39.31800M
Ebitda -21.87900M -29.21700M -37.10300M -50.39700M -39.32700M
Depreciation and amortization 5.67M 5.46M 5.51M 0.11M -0.00900M
Non operating income net other - - - - -
Operating income -27.87300M -34.49800M -41.34200M -50.50600M -39.31800M
Other operating expenses 116.37M 105.82M 90.43M 88.72M 93.82M
Interest expense 7.72M 8.26M 9.54M 8.07M 4.51M
Tax provision - - - - -
Interest income - - - - -
Net interest income -7.71600M -8.25800M -9.75700M -8.07200M -4.50800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 5.34M 14.94M 1.32M
Total revenue 88.50M 71.32M 49.09M 38.21M 54.51M
Total operating expenses 94.36M 90.25M 77.42M 74.56M 63.31M
Cost of revenue 21.91M 15.57M 13.01M 14.15M 30.52M
Total other income expense net -7.39200M -8.43300M -10.80400M -14.94100M -3.84100M
Discontinued operations - - - - -
Net income from continuing ops -35.26500M -42.93100M -63.34500M -65.44700M -43.15900M
Net income applicable to common shares - - - -65.44700M -43.15900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 87.48M 97.24M 99.10M 92.91M 76.10M
Intangible assets 3.88M 5.87M 7.91M 9.80M 11.62M
Earning assets - - - - -
Other current assets 4.50M 4.64M 4.22M 5.18M 7.25M
Total liab 89.94M 76.37M 94.52M 72.30M 56.37M
Total stockholder equity -2.46500M 20.88M 4.58M 20.61M 19.73M
Deferred long term liab - - - 0.65M -
Other current liab 12.03M 10.71M 29.86M 18.60M 25.43M
Common stock 0.00800M 0.14M 0.10M 0.08M 0.03M
Capital stock 0.00800M 0.14M 0.10M 0.08M 0.03M
Retained earnings -497.76200M -462.49700M -419.56600M -367.42000M -301.97300M
Other liab - - - 19.20M 17.42M
Good will 15.03M 15.03M 15.03M 15.03M 15.03M
Other assets - - - 5.92M 1.66M
Cash 18.99M 26.25M 26.38M 43.09M 32.71M
Cash and equivalents - - - - -
Total current liabilities 17.44M 14.32M 33.42M 22.84M 28.96M
Current deferred revenue 0.96M 0.68M 0.32M 0.96M 1.85M
Net debt 53.87M 35.73M 34.31M -11.23800M -22.70000M
Short term debt 1.37M 0.74M 0.30M 1.59M 0.02M
Short long term debt 0.00600M 0.02M 0.05M 0.05M 0.02M
Short long term debt total 72.85M 61.98M 60.69M 31.85M 10.01M
Other stockholder equity 495.29M 483.23M 424.05M 387.95M 321.67M
Property plant equipment - - - 8.82M 4.18M
Total current assets 32.52M 39.48M 39.68M 53.33M 43.61M
Long term investments - - - - -
Net tangible assets - - - -4.22200M -6.92100M
Short term investments - - - - -
Net receivables 9.04M 8.60M 7.68M 5.07M 3.66M
Long term debt 47.45M 36.41M 35.23M 25.00M 9.99M
Inventory - - 1.40M 1.40M 2.90M
Accounts payable 3.08M 2.19M 2.93M 1.69M 1.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.23M 7.26M 6.86M 5.92M 1.66M
Deferred long term asset charges - - - - -
Non current assets total 54.96M 57.76M 59.41M 39.57M 32.48M
Capital lease obligations 25.40M 25.55M 25.41M 6.80M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -3.44000M -22.04800M -3.53400M -2.54700M
Change to liabilities - - - -1.98600M -9.10700M
Total cashflows from investing activities -0.40300M -3.44000M -23.06200M -3.53400M -2.54700M
Net borrowings 9.98M -0.05100M 9.95M 16.50M -15.51400M
Total cash from financing activities 16.42M 52.05M 29.13M 58.88M 1.26M
Change to operating activities - - - -0.85700M 2.24M
Net income -35.26500M -42.93100M -52.14600M -65.44700M -43.15900M
Change in cash -7.25700M -0.03900M -16.80300M 10.38M -29.50800M
Begin period cash flow 26.33M 26.37M 43.17M 32.80M 62.31M
End period cash flow 19.07M 26.33M 26.37M 43.17M 32.80M
Total cash from operating activities -23.27100M -48.64900M -22.87000M -44.97200M -28.22300M
Issuance of capital stock 7.32M 55.62M 56.89M 59.54M 16.67M
Depreciation 5.67M 5.46M 5.51M 5.84M 3.18M
Other cashflows from investing activities -0.14400M -0.21000M -0.14300M - -
Dividends paid - - 0.64M - -0.32800M
Change to inventory 0.05M 0.02M 0.17M 0.91M 7.42M
Change to account receivables -0.53100M -1.81100M -4.71800M -1.50100M 11.45M
Sale purchase of stock 0.50M 0.62M 0.64M 0.35M 0.33M
Other cashflows from financing activities -0.84700M -3.52400M -8.94800M 27.59M 30.02M
Change to netincome - - - 18.98M 7.17M
Capital expenditures 0.26M 3.23M 23.06M 3.53M 2.55M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.33M -21.66900M 11.30M -4.34400M 4.59M
Stock based compensation 4.14M 6.64M 5.37M 5.96M 4.94M
Other non cash items 1.85M 3.86M 7.09M 13.01M 4.33M
Free cash flow -23.53000M -51.87900M -45.93200M -48.50600M -30.77000M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BDSX
Biodesix Inc		 0.66 4.27% 16.10 - - 1.47 44.57 2.11 -2.7189
TMO
Thermo Fisher Scientific Inc		 -8.13 1.69% 473.95 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 1.97 1.12% 178.08 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.35 1.74% 137.40 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 9.91 1.80% 560.73 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Biodesix Inc

919 West Dillon Road, Louisville, CO, United States, 80027

Key Executives

Name Title Year Born
Mr. Scott Hutton Pres, CEO & Director 1972
Ms. Robin Harper Cowie CFO, Sec. & Treasurer 1980
Mr. Ryan H. Siurek Chief Accounting Officer 1972
Dr. Heinrich Röder Founder & CTO NA
Dr. Robert W. Georgantas III, Ph.D. Chief Scientific Officer 1971
Mr. Jeffrey A. Bojar VP of Legal and Regulatory Affairs NA
Mr. Matt Stauffer VP of Sales NA
Dr. Paul J. Beresford Chief Bus. Officer NA
Dr. Gary Anthony Pestano Ph.D. Chief Devel. Officer 1967
Ms. Bobbi Coffin Chief Growth Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.